



**Rwanda**

**Country Operational Plan**

**FY 2015**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD				0	2,492,189
HHS/CDC	1,440,625	42,258,400		43,699,025	1,081,362
PC				0	684,591
State/PRM		340,581		340,581	0
USAID		27,246,095	0	27,246,095	4,456,157
<b>Total</b>	<b>1,440,625</b>	<b>69,845,076</b>	<b>0</b>	<b>71,285,701</b>	<b>8,714,299</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency					On Hold Amount	Total
	DOD	HHS/CDC	PC	State/PRM	USAID		
CIRC	0	49,478			109,432	0	158,910
HBHC	0	4,920,943		81,222	5,372,999	0	10,375,164
HKID					5,294,415	0	5,294,415
HLAB	0	1,603,945			690,280	0	2,294,225
HMBL		536,619				0	536,619
HMIN		13,889				0	13,889
HTXD		25,252			10,507,385	0	10,532,637
HTXS	0	11,090,037		65,026	1,964,513	0	13,119,576
HVCT	0	1,743,167		43,214	533,347	0	2,319,728
HVMS	0	3,442,910	0		0	0	3,442,910
HVOP	0	857,103		107,144	368,978	0	1,333,225
HVSI	0	1,844,796			0	0	1,844,796
HVTB	0	1,519,684		21,213	37,191	0	1,578,088
MTCT	0	1,680,151		10,731	372,283	0	2,063,165
OHSS		11,252,665			1,100,000	0	12,352,665
PDCS	0	1,621,467		4,502	673,980	0	2,299,949



PDX	0	1,496,919		7,529	221,292	0	<b>1,725,740</b>
	<b>0</b>	<b>43,699,025</b>	<b>0</b>	<b>340,581</b>	<b>27,246,095</b>	<b>0</b>	<b>71,285,701</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	10,213,537	0
HKID	5,294,415	0
HVTB	1,442,558	0
PDCS	2,218,293	0
<b>Total Technical Area Planned Funding:</b>	<b>19,168,803</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,860,690	0
HVSI	900,000	0
OHSS	11,800,000	0
<b>Total Technical Area Planned Funding:</b>	<b>14,560,690</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	149,650	0
HMBL	500,000	0
HMIN	0	0
HVCT	2,211,137	0
HVOP	1,243,994	0
MTCT	1,984,877	0
<b>Total Technical Area Planned Funding:</b>	<b>6,089,658</b>	<b>0</b>



**Technical Area: Treatment**

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	10,507,385	0
HTXS	13,018,558	0
PDTX	1,623,041	0
<b>Total Technical Area Planned Funding:</b>	<b>25,148,984</b>	<b>0</b>

## Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		158,535
	Number of new ANC and L&D clients		163,243
	By: Known positives at entry		6,221
	By: Number of new positives identified		2,799
	Sum of Positives Status disaggregates		9,020
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		

	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		
	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		



	Number of new ANC and L&D clients		0
	By: Known positives at entry		
	By: Number of new positives identified		0
	Sum of Positives Status disaggregates		0
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator:		

	15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	n/a	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		4,194
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)		4,195
	Life-long ART (including Option B+)		
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy		4,162
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		31

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)		0
	Single-dose nevirapine (with or without tail)		0
	Sum of Regimen Type disaggregates		0
	Sum of New and Current disaggregates		4,193
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	n/a	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		0
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)		0

	Life-long ART (including Option B+)		
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy		0
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)		
	Single-dose nevirapine (with or without tail)		
	Sum of Regimen Type disaggregates		
	Sum of New and Current disaggregates		0
PMTCT_FO_DSD	PMTCT_FO_DSD Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		3,881
	Number of HIV-exposed infants registered in the birth		3,936

	cohort at any time between 0 and 18 months of age (including transfer-ins)		
	HIV-infected: Linked to ART		0
	HIV-infected: Not linked to ART		0
	HIV-infected: Unknown link		
	HIV-uninfected: Not breastfeeding		22
	HIV-uninfected: Still breastfeeding		0
	HIV-uninfected: Breastfeeding status unknown		0
	Other: In care but no test done		0
	Other: Lost to follow-up		4
	Other: Died		0
	Other: Transferred out		0
PMTCT_FO_TA	PMTCT_FO_TA Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		0
	Number of HIV-exposed infants registered in the birth cohort at any time between 0 and 18 months of age (including transfer-ins)		0
	HIV-infected: Linked to ART		

	HIV-infected: Not linked to ART		
	HIV-infected: Unknown link		
	HIV-uninfected: Breastfeeding status unknown		
	HIV-uninfected: Not breastfeeding		
	HIV-uninfected: Still breastfeeding		
	Other: Died		
	Other: In care but no test done		
	Other: Lost to follow-up		
	Other: Transferred out		
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months		0
	Sex: Male		0
	Sex: Female		0
	Sum of Sex disaggregates		0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)		149
	By AE type: Number of		

	VMMC clients with one or more moderate or severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of		

	VMMC clients with one or more moderate or severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period		38,094
	By Age: <1		0
	By Age: 1-9		0
	By Age: 10-14		1,360
	By Age: 15-19		15,753
	By Age: 20-24		12,610
	By Age: 25-29		5,893
	By Age: 30-49		2,253
	By Age: 50+		225
	Sum of age disaggregates		29,948
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)		173

	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)		37,909
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site		12
	By circumcision technique: Surgical VMMC		13,576
	By circumcision technique: Device-based VMMC		24,518
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery		13,576
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery		0
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during		22,248

	the reporting period.		
	Total number of people in the target population		61,412
	Age/sex: 10-14 Male		341
	Age/sex: 15-19 Male		1,211
	Age/sex: 20-24 Male		3,450
	Age/sex: 25-49 Male		4,910
	Age/sex: 50+ Male		1,448
	Age/sex: 10-14 Female		562
	Age/sex: 15-19 Female		2,010
	Age/sex: 20-24 Female		4,022
	Age/sex: 25-49 Female		3,447
	Age/sex: 50+ Female		832
	Sum of Age/Sex disaggregates		22,233
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required		7,412
	Total estimated number of key population in the catchment area		
	By key population type:		5,846

	<p>Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>		
	<p>By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>		0
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>		0
	<p>By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based</p>		789

	on evidence and/or meet the minimum standards required)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key		

	population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months		1,682,443
	By Test Result: Negative		1,643,761
	By Test Result: Positive		29,580
	Sum of Test Result disaggregates		1,673,341
	Test Result by Age and Sex: Positive: <1 Male		6
	Test Result by Age and Sex: Positive: 1-4 Male		198
	Test Result by Age and Sex: Positive: 5-9 Male		56
	Test Result by Age and Sex: Positive: 10-14 Male		130
	Test Result by Age and Sex: Positive: 15-19 Male		740
	Test Result by Age and Sex: Positive: 20-24 Male		2,229
	Test Result by Age and Sex: Positive: 25-49 Male		8,834
	Test Result by Age and Sex: Positive: 50+ Male		927

	Test Result by Age and Sex: Positive: <1 Female		127
	Test Result by Age and Sex: Positive: 1-4 Female		244
	Test Result by Age and Sex: Positive: 5-9 Female		47
	Test Result by Age and Sex: Positive: 10-14 Female		178
	Test Result by Age and Sex: Positive: 15-19 Female		1,442
	Test Result by Age and Sex: Positive: 20-24 Female		3,880
	Test Result by Age and Sex: Positive: 25-49 Female		10,928
	Test Result by Age and Sex: Positive: 50+ Female		353
	Test Result by Age and Sex: Negative: <1 Male		4,887
	Test Result by Age and Sex: Negative: 1-4 Male		12,987
	Test Result by Age and Sex: Negative: 5-9 Male		18,758
	Test Result by Age and Sex: Negative: 10-14 Male		42,440
	Test Result by Age and Sex: Negative: 15-19 Male		85,925
	Test Result by Age and Sex: Negative: 20-24 Male		140,333
	Test Result by Age and Sex: Negative: 25-49 Male		477,504
	Test Result by Age and Sex: Negative: 50+ Male		69,817
	Test Result by Age and Sex: Negative: <1 Female		4,036

	Test Result by Age and Sex: Negative: 1-4 Female		11,606
	Test Result by Age and Sex: Negative: 5-9 Female		16,965
	Test Result by Age and Sex: Negative: 10-14 Female		30,309
	Test Result by Age and Sex: Negative: 15-19 Female		68,798
	Test Result by Age and Sex: Negative: 20-24 Female		123,273
	Test Result by Age and Sex: Negative: 25-49 Female		484,045
	Test Result by Age and Sex: Negative: 50+ Female		58,030
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		79,931
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		785,622
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		63,967
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		746,211
	Sum of Aggregated Age/Sex <15		143,898
	Sum of Aggregated Age/Sex 15+		1,531,833
	Sum of Aggregated Age/Sex disaggregates		1,675,731
	Service Delivery Point by Result: Antenatal Clinic - All		

	results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		53
	Service Delivery Point by Result: Antenatal Clinic - Negative		1,447
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by		60

	Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis - Positive		21
	Service Delivery Point by Result: Tuberculosis - Negative		39
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		890
	Service Delivery Point by Result: Outpatient Department - Positive		32
	Service Delivery Point by Result: Outpatient Department - Negative		858
	Service Delivery Point by Result: Inpatient – All Results		761
	Service Delivery Point by Result: Inpatient - Positive		27
	Service Delivery Point by Result: Inpatient - Negative		734
	Service Delivery Point by Result: HIV care and		

	treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		4,000
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		120
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		3,880
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		302
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		7,487
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling		

	& Testing (stand alone) – Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		
	Service Delivery Point by Result: Mobile – All Results		50,305
	Service Delivery Point by Result: Mobile - Positive		3,838
	Service Delivery Point by Result: Mobile - Negative		37,477
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status,		3,219

	during the reporting period.		
	Total number of registered new and relapsed TB cases, during the reporting period.		3,246
	Sex: Male		1,395
	Sex: Female		1,824
	Age: <1		0
	Age: 1-4		7
	Age: 5-9		41
	Age: 10-14		60
	Age 15-19		
	Age: 20+		2,956
	Status: Positive		50
	Status: Negative		146
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		0
	Total number of registered new and relapsed TB cases, during the reporting period.		0
	Age 15-19		
	Age: <1		0
	Age: 1-4		0
	Age: 10-14		0
	Age: 20+		0
	Age: 5-9		0
	Sex: Female		

	Sex: Male		
	Status: Negative		
	Status: Positive		
GEND_GBVDSD	Number of people receiving post-GBV care		6,460
	Age/Sex: <10 Male		441
	Age/Sex: 10-14 Male		78
	Age/Sex: 15-17 Male		56
	Age/Sex: 18-24 Male		168
	Age/Sex: 25+ Male		518
	Age/Sex: <10 Female		502
	Age/Sex: 10-14 Female		505
	Age/Sex: 15-17 Female		756
	Age/Sex: 18-24 Female		983
	Age/Sex: 25+ Female		1,479
	Sum of Age/Sex Disaggregates		5,486
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)		1,310
	By type of service: Sexual Violence (Post-Rape Care)		1,902
By PEP service provision (related to sexual violence services provided)			
GEND_NORMDSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria		2,520
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Male		

	Age/Sex: 25+ Male		
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20-24 Female		
	Age/Sex: 25+ Female		
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		
	By Age: 20-24		
	By Age: 25+		
	Sum of Age disaggregates		
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services		64,773
	Age/Sex: <1 Male		734
	Age/Sex: 1-4 Male		3,760
	Age/Sex: 5-9 Male		4,160
	Age/Sex: 10-14 Male		5,144
	Age/Sex: 15-17 Male		4,508
	Age/Sex: 18-24 Male		3,441
	Age/Sex: 25+ Male		7,941
	Age/Sex: <1 Female		735
	Age/Sex: 1-4 Female		4,053
	Age/Sex: 5-9 Female		4,287
	Age/Sex: 10-14 Female		5,434
	Age/Sex: 15-17 Female		4,956
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		3,854
Age/Sex: 25+ Female		11,766	

	Sum of Age/Sex disaggregates		64,773
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS		129,542
	Age/Sex: <1 Male		1,465
	Age/Sex: 1-4 Male		7,531
	Age/Sex: 5-9 Male		8,427
	Age/Sex: 10-14 Male		10,291
	Age/Sex: 15-17 Male		8,956
	By: Age/sex: Male 18-24		6,792
	By: Age/sex: Male 25+		15,907
	Age/Sex: <1 Female		1,463
	Age/Sex: 1-4 Female		8,101
	Age/Sex: 5-9 Female		8,598
	Age/Sex: 10-14 Female		10,869
	Age/Sex: 15-17 Female		9,932
	By: Age/sex: 18-24 Female		7,588
	By: Age/sex: 25+ Female		23,622
	Sum of Age/Sex disaggregates		75,633
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support		



	Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age		

	and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS		



	countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		

	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection		

	Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries - By service, age		



	and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS		

	countries - By service, age and sex: Economic Strengthening Male 25+		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		105,673
	Age/sex: <1 Male		8
	Age/sex: 1-4 Male		387
	Age/sex: 5-9 Male		1,105
	Age/sex: 10-14 Male		1,200
	Age/sex: 15-19 Male		742
	Age/sex: 20-24 Male		2,331
	Age/sex: 25-49 Male		27,239
	Age/sex: 50+ Male		6,744
	Age/sex: <1 Female		9
	Age/sex: 1-4 Female		390
	Age/sex: 5-9 Female		1,109
	Age/sex: 10-14 Female		1,195
	Age/sex: 15-19 Female		1,276
	Age/sex: 20-24 Female		3,307
	Age/sex: 25-49 Female		46,751
	Age/sex: 50+ Female		11,880
	Sun of Age/Sex disaggregates		105,673
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		2,648
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		35,280

	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		2,654
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		62,144
	Sum of Aggregated Age/Sex disaggregates		102,726
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		1,190
	Age/sex: <1 Male		0
	Age/sex: 1-4 Male		0
	Age/sex: 5-9 Male		0
	Age/sex: 10-14 Male		6
	Age/sex: 15-19 Male		3
	Age/sex: 20-24 Male		8
	Age/sex: 25-49 Male		0
	Age/sex: 50+ Male		0
	Age/sex: <1 Female		0
	Age/sex: 1-4 Female		0
	Age/sex: 5-9 Female		6
	Age/sex: 10-14 Female		0
	Age/sex: 15-19 Female		0
	Age/sex: 20-24 Female		15
	Age/sex: 25-49 Female		1,033
	Age/sex: 50+ Female		263
	Sum of Age/Sex disaggregates		1,334

	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		0
	Sum of Aggregated Age/Sex disaggregates		0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		11,359
	Age/sex: <1 Male		0
	Age/sex: 1-4 Male		40
	Age/sex: 5-9 Male		179
	Age/sex: 10-14 Male		190
	Age/sex: 15-19 Male		70
	Age/sex: 20-24 Male		244
	Age/sex: 25-49 Male		2,944
	Age/sex: 50+ Male		687
	Age/sex: <1 Female		0
	Age/sex: 1-4 Female		39
	Age/sex: 5-9 Female		183

	Age/sex: 10-14 Female		188
	Age/sex: 15-19 Female		135
	Age/sex: 20-24 Female		409
	Age/sex: 25-49 Female		4,913
	Age/sex: 50+ Female		1,138
	Sum of Age/sex disaggregates		11,359
	Aggregated Age/sex: <15 Male		401
	Aggregated Age/sex: 15+ Male		3,886
	Aggregated Age/sex: <15 Female		405
	Aggregated Age/sex: 15+ Female		6,488
	Sum of Aggregated Age/sex disaggregates		11,180
CARE_NEW_TA	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		0
	Age/sex: <1 Female		0
	Age/sex: 1-4 Female		0
	Age/sex: 5-9 Female		0
	Age/sex: 10-14 Female		0
	Age/sex: 15-19 Female		0
	Age/sex: 20-24 Female		2
	Age/sex: 25-49 Female		131
	Age/sex: 50+ Female		9

	Age/sex: <1 Male		0
	Age/sex: 1-4 Male		0
	Age/sex: 5-9 Male		0
	Age/sex: 10-14 Male		0
	Age/sex: 15-19 Male		0
	Age/sex: 20-24 Male		1
	Age/sex: 25-49 Male		0
	Age/sex: 50+ Male		0
	Aggregated Age/sex: <15 Female		0
	Aggregated Age/sex: <15 Male		0
	Aggregated Age/sex: 15+ Female		0
	Aggregated Age/sex: 15+ Male		0
	Sum of Aggregated Age/sex disaggregates		11,180
	Sum of age/sex disaggregates		143
FN_ASSESS_DSD	FN_ASSESS_DSD Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		106,454
	Number of HIV positive adults and children who received care and treatment services		106,454
	Age: <1		42

	Age: 1-4		774
	Age: 5-14		4,482
	Age: 15-17		3,309
	Age: 18+ years		97,847
	Sum of Age disaggregates		106,454
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		8,664
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		96,077
	By Pregnancy/Postpartum Status: Pregnant		
	By Pregnancy/Postpartum Status: Postpartum		
FN_ASSESS_TA	FN_ASSESS_TA Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		0
	Number of HIV positive adults and children who received care and treatment services		0
	Age: <1		0
	Age: 1-4		0
	Age: 5-14		0
	Age: 15-17		0
	Age: 18+ years		0
	Sum of Age disaggregates		0

	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		203
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		1,830
	By Pregnancy/Postpartum Status: Pregnant		
	By Pregnancy/Postpartum Status: Postpartum		
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		683
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		746
	Age: <1		0
	Age: 1-4		0
	Age: 5-9		0
	Age: 10-14		3
	Age: 15-19		3
	Age: 20+		19
	Sum of Age disaggregates		25
	Male		10

	Female		19
	Sum of Sex disaggregates		29
	Newly tested		
	Known HIV-positive		11
	Sum of Test Status disaggregates		11
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age disaggregates		
	Timeliness: Art initiation <8 weeks of start of TB treatment		8
	Timeliness: Art initiation >8 weeks of start of TB treatment		18
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		0
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		0
	Age: <1		0
	Age: 1-4		

	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		0
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age disaggregates		
	Male		
	Female		0
	Sum of Sex disaggregates		0
	Known HIV-positive		
	Newly tested		
	Sum of Test Status disaggregates		
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_OUTCOME_DSD	TB_OUTCOME_DSD TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		4
	The total number of		4

	registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		
	Outcome by Age: Cured <1		0
	Outcome by Age: Cured 1-4		0
	Outcome by Age: Cured 5-9		0
	Outcome by Age: Cured 10-14		0
	Outcome by Age: Cured: 15-19		0
	Outcome by Age: Cured 20+		4
	Outcome by Age: Treatment Complete <1		0
	Outcome by Age: Treatment Complete 1-4		0
	Outcome by Age: Treatment Complete 5-9		0
	Outcome by Age: Treatment Complete 10-14		0
	Outcome by Age: Treatment Complete 15-19		0
	Outcome by Age: Treatment Complete 20+		0
	Outcome by Age: Treatment Failed <1		0
	Outcome by Age: Treatment Failed 1-4		0
	Outcome by Age: Treatment Failed 5-9		0
	Outcome by Age: Treatment Failed 10-14		0
	Outcome by Age: Treatment Failed 15-19		0



	Outcome by Age: Treatment Failed 20+		0
	Outcome by Age: Died <1		0
	Outcome by Age: Died 1-4		0
	Outcome by Age: Died 5-9		0
	Outcome by Age: Died 10-14		0
	Outcome by Age: Died 15-19		0
	Outcome by Age: Died 20+		0
	Outcome by Age: Lost to Follow-up <1		0
	Outcome by Age: Lost to Follow-up 1-4		0
	Outcome by Age: Lost to Follow-up 5-9		0
	Outcome by Age: Lost to Follow-up 10-14		0
	Outcome by Age: Lost to Follow-up 15-19		0
	Outcome by Age: Lost to Follow-up 20+		0
	Outcome by Age: Not Evaluated <1		0
	Outcome by Age: Not Evaluated 1-4		0
	Outcome by Age: Not Evaluated 5-9		0
	Outcome by Age: Not Evaluated 10-14		0
	Outcome by Age: Not Evaluated 15-19		0
	Outcome by Age: Not Evaluated 20+		0
	Outcome by Sex: Treatment Complete Female		

	Outcome by Sex: Treatment Complete Male		0
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		102,140
	Number of HIV positive adults and children who received at least one of the		105,673

	following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		20
	Age: 1-4		793
	Age: 5-9		2,163
	Age: 10-14		2,328
	Age: 15-19		1,949
	Age: 20+		94,887
	Sum of Age disaggregates		102,140
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		5,280
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		96,337
	Sum of Aggregated Age disaggregates		101,617
	Sex: Male		37,634
	Sex: Female		64,505
	Sum of Sex disaggregates		102,139
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		1,190
	Number of HIV positive		1,190

	adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		0
	Age: 1-4		0
	Age: 5-9		0
	Age: 10-14		0
	Age: 15-19		0
	Age: 20+		0
	Sum of Age disaggregates		0
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		238
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		1,906
	Sum of Aggregated Age disaggregates		2,144
	Sex: Female		0
	Sex: Male		0
	Sum of Sex disaggregates		0
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		3,608

	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		3,587
	By infants who received their first virologic HIV test between 2 and 12 months of age		21
	Sum of Infant Age disaggregates		3,608
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		93
	Number of infants with a positive virological test result within 12 months of birth		0
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		13
	Number of HIV- positive pregnant women identified during the reporting period		

	(include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		0
	By infants who received their first virologic HIV test between 2 and 12 months of age		0
	Sum of Infant Age disaggregates		0
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		1
	Number of infants with a positive virological test result within 12 months of birth		
PMTCT_CTX_DSD	PMTCT_CTX_DSD Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		3,597
	Number of HIV-positive pregnant women identified in		

	the reporting period (include known HIV- positive at entry)		
PMTCT_CTX_TA	PMTCT_CTX_TA Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		18
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
CARE_COMM_DSD	Number of HIV-infected adults and children receiving care and support services outside of the health facility		13,049
	Age/Sex: <1 Male		142
	Age/Sex: 1-4 Male		755
	Age/Sex: 5-9 Male		833
	Age/Sex: 10-14 Male		848
	Age/Sex: 15-19 Male		776
	Age/Sex: 20-24 Male		775
	Age/Sex: 25-49 Male		1,361
	Age/Sex: 50+ Male		440
	Age/Sex: <1 Female		144
	Age/Sex: 1-4 Female		818
	Age/Sex: 5-9 Female		854

	Age/Sex: 10-14 Female		888
	Age/Sex: 15-19 Female		923
	Age/Sex: 20-24 Female		983
	Age/Sex: 25-49 Female		1,639
	Age/Sex: 50+ Female		782
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)		93,623
	Age/Sex: <1 Male		6
	Age/Sex: 1-4 Male		365
	Age/Sex: 5-14 Male		2,096
	Age/Sex: 15-19 Male		1,072
	Age/Sex: 20+ Male		31,878
	Age/Sex: <1 Female		7
	Age/Sex: 1-4 Female		343
	Age/Sex: 5-14 Female		2,111
	Age/Sex: 15-19 Female		2,818
	Age/Sex: 20+ Female		52,927
	Aggregated Age/Sex: <1 Male		6
	Aggregated Age/Sex: <1 Female		6
	Aggregated Age/Sex: 15+ Male		31,821
	Aggregated Age/Sex: 1-14 Female		2,340
	Aggregated Age/Sex: 15+ Female		54,607
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		86,428
	Sum of Aggregated Age/Sex		86,428

	disaggregates		
	Aggregated Age/Sex: 1-14 Male		2,344
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		4,696
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)		0
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 5-14 Male		0
	Age/Sex: 15-19 Male		0
	Age/Sex: 20+ Male		0
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		0
	Age/Sex: 5-14 Female		12
	Age/Sex: 15-19 Female		0
	Age/Sex: 20+ Female		0
	Sum of Age/Sex disaggregations		12
	Aggregated Age/Sex: <1 Male		2
	Aggregated Age/Sex: <1 Female		2
	Aggregated Age/Sex: 1-14 Male		264
	Aggregated Age/Sex: 15+ Male		3,089
	Aggregated Age/Sex: 1-14 Female		263
Aggregated Age/Sex: 15+ Female		5,469	
Sum of Aggregated Age/Sex			

	<15		
	Sum of Aggregated Age/Sex 15+		8,558
	Sum of Aggregated Age/Sex disaggregates		8,558
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		531
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)		11,518
	By Age/Sex: <1 Male		0
	By Age/Sex: 1-4 Male		62
	By Age/Sex: 5-9 Male		123
	By Age/Sex: 10-14 Male		104
	By Age/Sex: 15-19 Male		96
	By Age/Sex: 20-24 Male		215
	By Age/Sex: 25-49 Male		3,251
	By Age/Sex: 50+ Male		427
	By Age/Sex: <1 Female		2
	By Age/Sex: 1-4 Female		65
	By Age/Sex: 5-9 Female		124
	By Age/Sex: 10-14 Female		110
	By Age/Sex: 15-19 Female		336
	By Age/Sex: 20-24 Female		906
	By Age/Sex: 25-49 Female		5,672
	By Age/Sex: 50+ Female		25
	Sum of Age/Sex disaggregates		11,518
	Aggregated Grouping by Age: <1 Male		0
	Aggregated Grouping by Age/Sex: 1-14 Male		274
Aggregated Grouping by		3,889	

	Age/Sex: 15+ Male		
	Aggregated Grouping by Age/Sex: <1 Female		2
	Aggregated Grouping by Age/Sex: 15+ Female		6,882
	Sum of Aggregated Age/Sex disaggregates		10,771
	Pregnancy status		35
	Breastfeeding status		15
	Aggregated Grouping by Age/Sex: 1-14 Female		287
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)		0
	By Age/Sex: <1 Male		0
	By Age/Sex: 1-4 Male		0
	By Age/Sex: 5-9 Male		0
	By Age/Sex: 10-14 Male		0
	By Age/Sex: 15-19 Male		2
	By Age/Sex: 20-24 Male		0
	By Age/Sex: 25-49 Male		16
	By Age/Sex: 50+ Male		0
	By Age/Sex: <1 Female		0
	By Age/Sex: 1-4 Female		0
	By Age/Sex: 5-9 Female		1
	By Age/Sex: 10-14 Female		0
	By Age/Sex: 15-19 Female		1
	By Age/Sex: 20-24 Female		6
	By Age/Sex: 25-49 Female		0
	By Age/Sex: 50+ Female		0
	Sum of Age/Sex disaggregates		26
	Aggregated Grouping by		0

	Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		7
	Aggregated Grouping by Age/Sex: 15+ Male		0
	Aggregated Grouping by Age: <1 Female		0
	Aggregated Grouping by Age/Sex: 1-14 Female		1
	Aggregated Grouping by Age/Sex: 15+ Female		218
	Sum of Aggregated Age/Sex disaggregates		218
	Pregnancy status		
	Breastfeeding status		
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		11,877
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		12,454
	Age/Sex: <5 Male (Numerator: Number of adults and children who are		16

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		249
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		131
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		3,975
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		16
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		247
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are		351

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		6,890
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		18
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		253
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		140

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		4,221
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		18
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		256
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who		379

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		7,169
	Numerator by Status: Pregnant		35
	Numerator by Status: Breastfeeding		15
	Denominator by Status: Pregnant		35
	Denominator by Status: Breastfeeding		15
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		0
	Total number of adults and		0

	children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating		0

	ART)		
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		0
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		0

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who		0



	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		0
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage	n/a	

	of ART patients with an undetectable viral load at 12 months after initiation of ART		
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		78,848
	Number of adults and children on ART at least 6 months whose medical records were reviewed		87,571
	Age/Sex: <1 Male		1
	Age/Sex: 1-4 Male		298
	Age/Sex: 5-14 Male		1,738
	Age/Sex: 15-19 Male		846
	Age/Sex: 20+ Male		26,483
	Age/Sex: <1 Female		8
	Age/Sex: 1-4 Female		302
	Age/Sex: 5-14 Female		1,738
	Age/Sex: 15-19 Female		2,367
	Age/Sex: 20+ Female		45,063
	Results Category: Undetectable		990
	Results Category: Detectable		249
TX_VIRAL_TA	TX_VIRAL_TA Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months.		0

	Number of adults and children on ART at least 6 months whose medical records were reviewed.		0
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 5-14 Male		0
	Age/Sex: 15-19 Male		0
	Age/Sex: 20+Male		0
	Age/Sex: <1 Female		0
	Age/Ses: 1-4 Female		0
	Age/Sex: 5-14 Female		0
	Age/Sex: 15-19 Female		0
	Age/Sex: 20+ Female		0
	Result Category: Undetectable		709
	Result Category: Detectable		115
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		43
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests		246
	By clinical laboratories		246
	By Point-of-care testing sites		0

LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program		
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing		525
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		475
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		450
	CD4: Number of laboratories that perform this testing		76
	CD4: Number of laboratories that participate in this PT program		76
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		76
	Early infant diagnostics: Number of laboratories that perform this testing		2
	Early infant diagnostics: Number of laboratories that		2

	participate in this PT program		
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		2
	HIV viral load: Number of laboratories that perform this testing		9
	HIV viral load: Number of laboratories that participate in this PT program		9
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		9
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		201
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		40
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		40
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this		16

	testing		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		1
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		1
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		1
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		68,171

	Number of viral load tests performed from adults and children on ART within the current reporting period		80,588
	Age/Sex: <1 Male		1
	Age/Sex: 1-4 Male		266
	Age/Sex: 5-14 Male		1,502
	Age/Sex: 15-19 Male		724
	Age/Sex: 20+ Male		22,859
	Age/Sex: <1 Female		1
	Age/Sex: 1-4 Female		263
	Age/Sex: 5-14 Female		1,525
	Age/Sex: 15-19 Female		2,046
	Age/Sex: 20+ Female		38,983
	Pregnant		31
	Breastfeeding		12
	Test indication: Routine monitoring		655
	Test indication: Targeted monitoring		
TX_UNDETECT_TA	TX_UNDETECT_TA Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
TX_UNDETECT_TA	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		0
TX_UNDETECT_TA	Number of viral load tests performed from adults and children on ART within the current reporting period		0

	Age/Sex: <1 Female		0
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Female		0
	Age/Sex: 1-4 Male		1
	Age/Sex: 15-19 Female		0
	Age/Sex: 15-19 Male		9
	Age/Sex: 20+ Female		1,508
	Age/Sex: 20+ Male		0
	Age/Sex: 5-14 Female		0
	Age/Sex: 5-14 Male		15
	Breastfeeding		
	Pregnant		
	Test indication: Routine monitoring		
	Test indication: Targeted monitoring		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre		1,046
	By Graduates: Doctors		163
	By Graduates: Nurses		576
	By Graduates: Midwives		199
	By Graduates: Social service workers		
	By Graduates: Laboratory professionals		89
	By Graduates: Other		19
	Sum of Graduates		1,046

	disaggregates		
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	n/a	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		197
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment		197
	Service delivery type: Care and Support		3
	Service delivery type: Treatment		2
	Service delivery type: PMTCT		2
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		

## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7158	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	19,914,531
7162	U.S. Agency for International Development (USAID)	Other USG Agency	U.S. Agency for International Development	GHP-State	238,118
7335	American Refugee Committee	NGO	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	0
9978	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
10193	Treatment and Research AIDS Center	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10825	Ministry of Health, Rwanda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0



			Prevention		
10954	Drew University	University	U.S. Department of Defense	GHP-State	0
10981	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	340,581
12140	Rwanda School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12141	Kigali Health Institute	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13598	JHPIEGO	University	U.S. Department of Defense	GHP-State	0
13704	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	786,753
14287	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	0
16857	African	FBO	U.S. Agency for	GHP-State	694,050

	Evangelistic Enterprise		International Development		
16858	Caritas Rwanda	FBO	U.S. Agency for International Development	GHP-State	826,912
16859	Society for Family Health	NGO	U.S. Agency for International Development	GHP-State	0
16860	François Xavier Bagnoud	NGO	U.S. Agency for International Development	GHP-State	697,544
17616	CHF International	NGO	U.S. Agency for International Development	GHP-State	4,874,940
17618	Society for Family Health	NGO	U.S. Department of Defense	GHP-State	0
17619	Emory University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,049,978
17621	Ministry of Health, Rwanda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,500,000
17623	Ministry of Health, Rwanda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	20,598,825

			Control and Prevention		
17625	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,445,903



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7158</b>	<b>Mechanism Name: SCMS</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 19,914,531</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	19,914,531

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	112,887
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	150,516
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

### Key Issues



(No data provided.)

### Budget Code Information

<b>Mechanism ID: 7158</b>			
<b>Mechanism Name: SCMS</b>			
<b>Prime Partner Name: Partnership for Supply Chain Management</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	4,135,511	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	37,191	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	243,297	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	690,280	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	109,432	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	533,347	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	372,283	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXD	10,507,385	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,964,513	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	221,292	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 7162</b>	<b>Mechanism Name: Central Contraceptive Procurement</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: U.S. Agency for International Development (USAID)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 238,118</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	238,118

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Condom procurement	238,118
--------------------	---------



### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	7162		
<b>Mechanism Name:</b>	Central Contraceptive Procurement		
<b>Prime Partner Name:</b>	U.S. Agency for International Development (USAID)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	238,118	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 7335</b>	<b>Mechanism Name: ARC</b>
Funding Agency: State/PRM	Procurement Type: Contract
Prime Partner Name: American Refugee Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 7335			
<b>Mechanism Name:</b> ARC			
<b>Prime Partner Name:</b> American Refugee Committee			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 9978</b>	<b>Mechanism Name: ROADS III</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 427,739</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 9978			
<b>Mechanism Name:</b> ROADS III			
<b>Prime Partner Name:</b> FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID:</b> 10193	<b>Mechanism Name:</b> TRAC Cooperative Agreement
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Treatment and Research AIDS Center	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 10193			
<b>Mechanism Name:</b> TRAC Cooperative Agreement			
<b>Prime Partner Name:</b> Treatment and Research AIDS Center			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10825</b>	<b>Mechanism Name: MoH CoAg</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Rwanda	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 10825</b>			
<b>Mechanism Name: MoH CoAg</b>			
<b>Prime Partner Name: Ministry of Health, Rwanda</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details



<b>Mechanism ID: 10954</b>	<b>Mechanism Name: HIV Care and Treatment to the Rwanda Defense Forces (RDF)</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Drew University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 1,125,730</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 10954</b>			
<b>Mechanism Name: HIV Care and Treatment to the Rwanda Defense Forces (RDF)</b>			
<b>Prime Partner Name: Drew University</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 10981</b>	<b>Mechanism Name: UNHCR</b>
Funding Agency: State/PRM	Procurement Type: Grant
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 340,581</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	340,581

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	115,000
Food and Nutrition: Policy, Tools, and Service Delivery	35,000
Key Populations: FSW	15,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	25,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Sub Area:	Capacity building



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 10981			
<b>Mechanism Name:</b> UNHCR			
<b>Prime Partner Name:</b> United Nations High Commissioner for Refugees			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	81,222	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	21,213	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	4,502	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	43,214	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	107,144	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	10,731	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	65,026	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	7,529	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 12140</b>	<b>Mechanism Name: National University of Rwanda School of Public Health</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Rwanda School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information



<b>Mechanism ID:</b> 12140			
<b>Mechanism Name:</b> National University of Rwanda School of Public Health			
<b>Prime Partner Name:</b> Rwanda School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 12141		<b>Mechanism Name:</b> Kigali Health Institute	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Kigali Health Institute			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: Yes		Managing Agency: HHS/CDC	

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 12141			
<b>Mechanism Name:</b> Kigali Health Institute			
<b>Prime Partner Name:</b> Kigali Health Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID:</b> 13598	<b>Mechanism Name:</b> Rwanda Defense Health Program for HIV/AIDS Prevention, Care and Treatment in Foreign Militaries
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 500,000	
Funding Source	Funding Amount
GHP-State	0



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13598		
<b>Mechanism Name:</b>	Rwanda Defense Health Program for HIV/AIDS Prevention, Care and		
<b>Prime Partner Name:</b>	Treatment in Foreign Militaries		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13704</b>	<b>Mechanism Name: PARTNERSHIP FOR ADVANCED CLINICAL MENTORSHIP (PACM)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 786,753</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	786,753

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	51,617
Key Populations: FSW	30,976
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Food and Nutrition: Policy, Tools, and Service Delivery	20,277
Key Populations: MSM and TG	20,277
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs

**Key Issues**



(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13704			
<b>Mechanism Name:</b> PARTNERSHIP FOR ADVANCED CLINICAL MENTORSHIP (PACM)			
<b>Prime Partner Name:</b> University of Maryland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	285,536	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	76,702	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	87,683	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	204,866	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	131,966	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14287	<b>Mechanism Name:</b> Family Health Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 14287</b>			
<b>Mechanism Name: Family Health Project</b>			
<b>Prime Partner Name: Chemonics International</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16857</b>	<b>Mechanism Name: Ubaka Ejo</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: African Evangelistic Enterprise	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 694,050</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	694,050



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	40,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Water	50,000
Education	240,000
Economic Strengthening	300,000
Human Resources for Health	90,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 16857			
<b>Mechanism Name:</b> Ubaka Ejo			
<b>Prime Partner Name:</b> African Evangelistic Enterprise			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	294,194	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	299,919	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	71,981	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	27,956	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16858</b>	<b>Mechanism Name: Gimbuka</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Caritas Rwanda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 826,912</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	826,912

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Water	67,648
Economic Strengthening	289,919
Gender: Gender Equality	48,320
Focus Area:	Increase gender-equitable access to income and



	productive resources, including education
Sub Area:	Implementation
Gender: GBV	48,320
Focus Area:	GBV Prevention
Education	289,919
Food and Nutrition: Commodities	67,648
Food and Nutrition: Policy, Tools, and Service Delivery	28,991
Human Resources for Health	28,991

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 16858</b>			
<b>Mechanism Name: Gimbuka</b>			
<b>Prime Partner Name: Caritas Rwanda</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	382,287	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	318,294	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	87,129	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	39,202	0
------------	------	--------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16859</b>	<b>Mechanism Name: Rwanda Social Marketing Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Society for Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 776,374</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 16859			
<b>Mechanism Name:</b> Rwanda Social Marketing Program			
<b>Prime Partner Name:</b> Society for Family Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 16860	<b>Mechanism Name:</b> Turengere Abana
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: François Xavier Bagnoud	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 697,544	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	697,544

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Economic Strengthening	300,000
Gender: GBV	45,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Water	55,000
Education	160,000
Human Resources for Health	50,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 16860</b>			
<b>Mechanism Name: Turengere Abana</b>			
<b>Prime Partner Name: François Xavier Bagnoud</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	290,498	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	301,860	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	79,816	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	25,370	0
------------	------	--------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17616</b>	<b>Mechanism Name: Twiyubake</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: CHF International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,874,940</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,874,940

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	150,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Education	500,000



Economic Strengthening	1,350,000
Food and Nutrition: Policy, Tools, and Service Delivery	400,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17616			
<b>Mechanism Name:</b> Twiyubake			
<b>Prime Partner Name:</b> CHF International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	270,509	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,374,342	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	191,757	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	38,332	0

### Implementing Mechanism Indicator Information

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 17618</b>	<b>Mechanism Name: Rwanda Defense HIV Prevention Program</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Society for Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 591,459</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17618		
<b>Mechanism Name:</b>	Rwanda Defense HIV Prevention Program		
<b>Prime Partner Name:</b>	Society for Family Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17619</b>	<b>Mechanism Name: Implementing Evidence-Based Prevention Intervention for Key Populations in Republic of Rwanda under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Emory University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,049,978</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,049,978

### Sub Partner Name(s)

Custom



(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	23,431
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Gender: GBV	23,431
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Key Populations: FSW	468,824
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	281,239
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17619		
<b>Mechanism Name:</b>	Implementing Evidence-Based Prevention Intervention for Key Populations in Republic of Rwanda under PEPFAR		
<b>Prime Partner Name:</b>	Emory University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	237,055	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	439,047	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	373,876	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 17621</b>	<b>Mechanism Name: Strengthening Human Resources for Health Capacity in the Republic of Rwanda under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Rwanda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 10,500,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	10,500,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	10,500,000
----------------------------	------------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17621
<b>Mechanism Name:</b>	Strengthening Human Resources for Health Capacity in the Republic of Rwanda under PEPFAR
<b>Prime Partner Name:</b>	Ministry of Health, Rwanda



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	10,500,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17623</b>	<b>Mechanism Name: Strengthening HIV Clinical Services in the Republic of Rwanda under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Rwanda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 20,598,825</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	20,598,825

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	11,181,100
Food and Nutrition: Policy, Tools, and Service Delivery	40,658



Gender: GBV	81,317
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	40,600
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	35,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Gender: Gender Equality	40,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information



<b>Mechanism ID:</b>	17623		
<b>Mechanism Name:</b>	Strengthening HIV Clinical Services in the Republic of Rwanda under		
<b>Prime Partner Name:</b>	PEPFAR		
	Ministry of Health, Rwanda		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	3,801,277	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	963,874	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	1,331,641	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	350,410	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,127,427	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	393,996	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,246,444	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	10,248,153	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	985,603	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17625</b>	<b>Mechanism Name: Implementing Technical and Science Support Services (TSSS) in the Republic of Rwanda under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,445,903</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,445,903

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,700,930
Gender: GBV	2,112
Focus Area:	GBV Prevention

Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	2,112
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: FSW	3,056
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	2,785
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex



	partners
Focus Area:	Monitoring and evaluation of MSM/TG programs

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17625		
<b>Mechanism Name:</b>	Implementing Technical and Science Support Services (TSSS) in the		
<b>Prime Partner Name:</b>	Republic of Rwanda under PEPFAR		
	New Partner		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	435,448	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	420,280	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	131,468	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	820,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	750,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	200,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	40,218	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	68,102	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	267,736	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	536,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	276,651	0

### Implementing Mechanism Indicator Information

(No data provided.)



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		0		0	0
Computers/IT Services		0		0	157,000
ICASS		0		0	470,000
Indirect Costs		0		0	0
Institutional Contractors		0	0	0	675,000
Management Meetings/Professional Development		0		0	88,000
Non-ICASS Administrative Costs		0		0	83,650
Non-ICASS Motor Vehicles		0		0	0
Peace Corps Volunteer Costs				0	0
Staff Program Travel		0	0	0	37,000
USG Renovation		0		0	0
USG Staff Salaries and Benefits		0	0	0	1,741,394
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>3,252,044</b>



**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		0		0	5,000
ICASS		0		0	50,000
Non-ICASS Administrative Costs		0		0	5,000
Staff Program Travel				0	65,000
USG Staff Salaries and Benefits				0	150,000
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>275,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		0		0	320,312
Computers/IT Services		215,261		215,261	0
ICASS		1,430,000		1,430,000	0
Institutional Contractors		539,474		539,474	0
Management Meetings/Professional Development		0		0	28,000
Non-ICASS		0		0	411,314



Administrative Costs					
Non-ICASS Motor Vehicles		50,000		50,000	0
Staff Program Travel		53,617		53,617	321,736
USG Staff Salaries and Benefits	1,440,625	2,588,589		4,029,214	0
<b>Total</b>	<b>1,440,625</b>	<b>4,876,941</b>	<b>0</b>	<b>6,317,566</b>	<b>1,081,362</b>

### U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Non-ICASS Administrative Costs		0		0	304,453
Staff Program Travel				0	34,403
USG Staff Salaries and Benefits				0	345,735
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>684,591</b>